Venus Medtech Stock Performance

VMTHF Stock  USD 0.42  0.00  0.00%   
On a scale of 0 to 100, Venus Medtech holds a performance score of 8. The entity has a beta of -0.4, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Venus Medtech are expected to decrease at a much lower rate. During the bear market, Venus Medtech is likely to outperform the market. Please check Venus Medtech's treynor ratio and rate of daily change , to make a quick decision on whether Venus Medtech's existing price patterns will revert.

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Venus Medtech are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile technical indicators, Venus Medtech reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Begin Period Cash Flow2.7 B
Total Cashflows From Investing Activities-653 M
  

Venus Medtech Relative Risk vs. Return Landscape

If you would invest  30.00  in Venus Medtech on December 2, 2025 and sell it today you would earn a total of  12.00  from holding Venus Medtech or generate 40.0% return on investment over 90 days. Venus Medtech is currently producing 0.7231% returns and takes up 7.1318% volatility of returns over 90 trading days. Put another way, 64% of traded pink sheets are less volatile than Venus, and 86% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon Venus Medtech is expected to generate 9.41 times more return on investment than the market. However, the company is 9.41 times more volatile than its market benchmark. It trades about 0.1 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of risk.

Venus Medtech Target Price Odds to finish over Current Price

The tendency of Venus Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.42 90 days 0.42 
under 4
Based on a normal probability distribution, the odds of Venus Medtech to move above the current price in 90 days from now is under 4 (This Venus Medtech probability density function shows the probability of Venus Pink Sheet to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon Venus Medtech has a beta of -0.4. This entails as returns on the benchmark increase, returns on holding Venus Medtech are expected to decrease at a much lower rate. During a bear market, however, Venus Medtech is likely to outperform the market. Additionally Venus Medtech has an alpha of 0.7123, implying that it can generate a 0.71 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Venus Medtech Price Density   
       Price  

Predictive Modules for Venus Medtech

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Venus Medtech. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.020.427.50
Details
Intrinsic
Valuation
LowRealHigh
0.020.327.40
Details
Naive
Forecast
LowNextHigh
0.010.387.45
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.420.420.42
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Venus Medtech. Your research has to be compared to or analyzed against Venus Medtech's peers to derive any actionable benefits. When done correctly, Venus Medtech's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Venus Medtech.

Venus Medtech Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Venus Medtech is not an exception. The market had few large corrections towards the Venus Medtech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Venus Medtech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Venus Medtech within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.71
β
Beta against Dow Jones-0.4
σ
Overall volatility
0.06
Ir
Information ratio 0.09

Venus Medtech Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Venus Medtech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Venus Medtech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Venus Medtech is way too risky over 90 days horizon
Venus Medtech has some characteristics of a very speculative penny stock
Venus Medtech appears to be risky and price may revert if volatility continues
The company reported the revenue of 415.86 M. Net Loss for the year was (373.64 M) with profit before overhead, payroll, taxes, and interest of 324.34 M.
Venus Medtech has accumulated about 2.96 B in cash with (456.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.75, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 22.0% of the company outstanding shares are owned by insiders

Venus Medtech Fundamentals Growth

Venus Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Venus Medtech, and Venus Medtech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Venus Pink Sheet performance.

About Venus Medtech Performance

By analyzing Venus Medtech's fundamental ratios, stakeholders can gain valuable insights into Venus Medtech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Venus Medtech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Venus Medtech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Venus Medtech Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company was founded in 2009 and is headquartered in Hangzhou, the Peoples Republic of China. Venus Medtech operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 905 people.

Things to note about Venus Medtech performance evaluation

Checking the ongoing alerts about Venus Medtech for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Venus Medtech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Venus Medtech is way too risky over 90 days horizon
Venus Medtech has some characteristics of a very speculative penny stock
Venus Medtech appears to be risky and price may revert if volatility continues
The company reported the revenue of 415.86 M. Net Loss for the year was (373.64 M) with profit before overhead, payroll, taxes, and interest of 324.34 M.
Venus Medtech has accumulated about 2.96 B in cash with (456.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.75, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 22.0% of the company outstanding shares are owned by insiders
Evaluating Venus Medtech's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Venus Medtech's pink sheet performance include:
  • Analyzing Venus Medtech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Venus Medtech's stock is overvalued or undervalued compared to its peers.
  • Examining Venus Medtech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Venus Medtech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Venus Medtech's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Venus Medtech's pink sheet. These opinions can provide insight into Venus Medtech's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Venus Medtech's pink sheet performance is not an exact science, and many factors can impact Venus Medtech's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Venus Pink Sheet analysis

When running Venus Medtech's price analysis, check to measure Venus Medtech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Venus Medtech is operating at the current time. Most of Venus Medtech's value examination focuses on studying past and present price action to predict the probability of Venus Medtech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Venus Medtech's price. Additionally, you may evaluate how the addition of Venus Medtech to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Global Correlations
Find global opportunities by holding instruments from different markets
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
AI Portfolio Prophet
Use AI to generate optimal portfolios and find profitable investment opportunities
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.